SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellceutix Corporation.

NEW YORK, Sept. 17, 2015

The investigation concerns whether Cellceutix and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On August 6, 2015, SeekingAlpha.com published an article describing Cellceutix as an overvalued shell corporation run by a management team with a track record of self-enrichment, value destruction, and making false statements regarding their background and credentials. The article also asserted that the company's science is demonstrably unviable in that the antibiotic Brilacidin and anti-cancer drug Kevetrin are ineffective.

Following this news, the company's stock fell $0.34, or 16.5%, to close at $1.71 on August 6, 2015.

If you are aware of any facts relating to this investigation, or purchased shares of Cellceutix, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com